Lean NASH: distinctiveness and clinical implication
- PMID: 26202295
- DOI: 10.1007/s12072-013-9477-5
Lean NASH: distinctiveness and clinical implication
Abstract
Introduction: Non-alcoholic fatty liver (NAFL) in the absence of overweight and/or obesity, defined by the anthropometric parameter, body mass index (BMI), has been designated as 'lean NASH.' While maintaining a close pathophysiological link with metabolic syndrome (MS) and insulin resistance (IR), the presence of subtle alterations in measures of total body and regional adiposity not exceeding the designed cut-offs, are hallmarks of 'lean NASH.'
Material and methods: Available literature related to non-alcoholic steatohepatitis (NASH) in lean or non-obese individuals and its pathogenesis in general published in English language journals till the time of manuscript preparation were reviewed and critically analysed.
Analysis: Being a closely related but variant phenotype of NASH, its features metabolically resemble the well-characterized entity 'metabolically obese normal weight (MONW)' individuals. Apart from total body adiposity, distribution of fat in different body compartments has assumed greater pathophysiologic relevance in characterizing 'lean NASH'. Detection of NASH in stringently defined non-obese individuals, by both BMI and waist circumference indices, indicates existence of a subset of NASH in which fat compartmentalization at ectopic sites is not picked up by the anthropometric yardsticks used. Volume [Quantity] and biological behavior of the visceral and deep subcutaneous adipose tissues contribute to this variant of NASH in non-obese subjects. Genetic predisposition to IR and MS along with the environmental influences like childhood nutritional status, dietary composition and gut microbiome possibly play pathogenetic role.
Conclusion: The most important concern is in the principles of nomenclature within syndromes where clinical dissimilarities exist despite biological similarities. Till a uniformly acceptable pathophysiological and/or etiology-based classification emerges, the term "lean NASH" would continue to provide us an opportunity to ponder over and refine this subset of fatty liver in non-obese people and potentially significant liver disease.
Keywords: Adiposity; BMI; Lean; Obesity; Steatohepatitis; Waist circumference.
Similar articles
-
Offspring body size and metabolic profile - effects of lifestyle intervention in obese pregnant women.Dan Med J. 2014 Jul;61(7):B4893. Dan Med J. 2014. PMID: 25123127 Review.
-
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384. doi: 10.1016/j.numecd.2017.10.014. Epub 2017 Oct 26. Nutr Metab Cardiovasc Dis. 2018. PMID: 29482963
-
Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.Clin Obes. 2016 Apr;6(2):117-23. doi: 10.1111/cob.12132. Epub 2016 Feb 8. Clin Obes. 2016. PMID: 26856683
-
Body composition determinants of metabolic phenotypes of obesity in nonobese and obese postmenopausal women.Obesity (Silver Spring). 2013 Sep;21(9):1807-14. doi: 10.1002/oby.20227. Epub 2013 May 21. Obesity (Silver Spring). 2013. PMID: 23696298
-
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.World J Gastroenterol. 2016 Sep 28;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078. World J Gastroenterol. 2016. PMID: 27688650 Free PMC article. Review.
Cited by
-
The transcontinental variability of nonalcoholic fatty liver disease.Hepatoma Res. 2020;6:72. doi: 10.20517/2394-5079.2020.73. Epub 2020 Oct 12. Hepatoma Res. 2020. PMID: 36419503 Free PMC article.
-
Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study.J Transl Med. 2023 Oct 5;21(1):694. doi: 10.1186/s12967-023-04569-7. J Transl Med. 2023. PMID: 37798764 Free PMC article.
-
Lipid droplet biogenesis and functions in health and disease.Nat Rev Endocrinol. 2023 Aug;19(8):443-459. doi: 10.1038/s41574-023-00845-0. Epub 2023 May 23. Nat Rev Endocrinol. 2023. PMID: 37221402 Free PMC article. Review.
-
Gut microbiota in MAFLD: therapeutic and diagnostic implications.Ther Adv Endocrinol Metab. 2024 Apr 15;15:20420188241242937. doi: 10.1177/20420188241242937. eCollection 2024. Ther Adv Endocrinol Metab. 2024. PMID: 38628492 Free PMC article. Review.
-
Decreased intestinal abundance of Akkermansia muciniphila is associated with metabolic disorders among people living with HIV.Ann Med. 2025 Dec;57(1):2474730. doi: 10.1080/07853890.2025.2474730. Epub 2025 Mar 7. Ann Med. 2025. PMID: 40052450 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources